GelSight Unveils Sleek Next Generation Mobile 3D Measurement Device to Expand into New Industries
12.10.2021 16:00:00 EEST | Business Wire | Press release
GelSight, a pioneer in tactile imaging and sensing technology, today introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces, while maintaining accuracy, speed, and field of view.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005405/en/
GelSight Mobile™ Series 2 offers industry-leading, tactile measurement capabilities in a more compact, ergonomic package. (Photo: Business Wire)
GelSight’s technology enables digital tactile sensing with the sensitivity and resolution of human touch. Data captured by GelSight’s elastomeric tactile sensing platform leverages proprietary software and algorithms to provide detailed, accurate surface characterization that can generate significant gains in productivity both on the production floor and in the field while also reducing the costs associated with manual or tool-based visual inspection. The handheld GelSight Mobile device can be deployed on production and assembly lines to enable rapid and well documented quality assurance decisions. Dimensions of scratches, dents, hits, gaps, offset, hole diameter, and fastener flushness can be measured in high-resolution, on any surface, in seconds.
The Series 2 head size has been minimized, so it can be utilized across a wider variety of applications. This is especially critical in the automotive and aerospace industries where it can provide rapid, repeatable, non-destructive testing for manufacturing and maintenance, repair, and overhaul (MRO) of engines, fuselages, and other critical components.
The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.
“We took the accuracy, speed and mobility that our customers loved about the first-generation handheld device, and incorporated that into a smaller, more user-friendly form-factor that can deliver payback value in a matter of weeks in terms of saved production time, labor costs, and scrap,” said Youssef Benmokhtar, CEO, GelSight. “The introduction of Series 2 is ushering GelSight into a new era. We are digitizing tactile sensing to unlock new opportunities for in-line and off-line quality control innovation, across industries.”
“We use the GelSight Mobile for our MRO operations, and we are delighted to now incorporate the Mobile Series 2,” said Yann Siehen of Safran Helicopter Engines. “We had the opportunity to evaluate Series 2 and have been impressed by its performance. Its compact and lightweight design will definitely increase the number of use cases and will accelerate our return on investment.”
GelSight will be demoing the new device at the 2021 NBAA Business Aviation Convention & Exhibition (NBAA-BACE) October 12-14, 2021, in Las Vegas, NV at Booth #1224 – West Hall. To schedule a meeting and demo, please reach out to sales@gelsight.com.
The GelSight Mobile Series 2 is shipping now. To learn more about demo evaluations or purchasing, please email info@gelsight.com.
To learn more about GelSight, please visit https://gelsight.com/.
About GelSight
GelSight develops portable, non-destructive elastomeric 3D imaging systems used to improve quality control processes in aerospace, automotive and other high-value industries. The proprietary technology that was invented at the Massachusetts Institute of Technology provides extremely detailed and rapid surface measurements and robotic sensing capabilities. For more information, please visit https://gelsight.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005405/en/
Contact information
Media
Kalyn Schieffer for GelSight
kos@anzupartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom